Johnson & Johnson (NYSE: JNJ) has seen a notable rally in its stock price, driven by a solid third-quarter financial performance and strategic moves to sharpen its business focus. In mid-October, the company reported Q3 2025 revenue of $24 billion, up nearly 7% year-over-year and slightly ahead of market expectations. Adjusted earnings per share rose 15.7% to $2.80, surpassing consensus estimates by $0.03.
The better-than-expected results prompted management to raise its full-year revenue growth forecast to 5.7%, signaling confidence in sustained momentum. This optimistic outlook has reinforced investor sentiment toward the company’s resilient operations amid a dynamic market environment.
As part of its ongoing portfolio optimization, J&J also plans to spin off its underperforming orthopedics unit within the next two years. The move will allow the company to concentrate on higher-growth, higher-margin segments such as cardiovascular and surgical technologies—a shift viewed favorably by analysts.
On November 17, J&J announced it would acquire Halda Therapeutics, a clinical-stage biotech firm, for $3.05 billion in cash. The deal, expected to close in the coming months pending regulatory approvals, aims to strengthen J&J’s oncology division with Halda’s innovative oral targeted therapies for solid tumors, particularly prostate cancer.
The acquisition comes at a critical time. J&J faces mounting competition in key therapeutic areas such as oncology and immunology, where rivals like AbbVie are gaining ground. The pending patent expiration of Stelara, a blockbuster immunology drug, has also increased pressure on the company to replenish its pipeline through strategic deals.
Halda’s lead candidate, currently in early-stage trials, targets metastatic prostate cancer with a mechanism designed to overcome treatment resistance. Prostate cancer remains the most diagnosed cancer among American men and the second leading cause of male cancer deaths. By 2030, global cases are projected to reach 1.7 million annually. Beyond prostate cancer, Halda is also developing treatments for breast cancer and other solid tumors.
This transaction follows J&J’s $14.6 billion acquisition of Intra-Cellular Therapies in April—the largest biotech deal of the year—which added promising neuroscience assets to its portfolio.
Through a combination of disciplined portfolio management and targeted acquisitions, Johnson & Johnson continues to position itself for long-term growth in high-value therapeutic areas. Investors are closely watching how the healthcare leader balances innovation and operational excellence to navigate industry challenges and capitalize on emerging opportunities.
